Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

168 results about "Kidney disorder" patented technology

Impairment of health or a condition of abnormal functioning of the kidney.

Methods and devices for renal nerve blocking

A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump or a drug eluding implant for targeted delivery of a nerve-blocking agent to the periarterial space of the renal artery.
Owner:MEDTRONIC ARDIAN LUXEMBOURG SARL

Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides

InactiveUS20120220528A1Lower elevated filing pressureImproves dyspneaPeptide/protein ingredientsPharmaceutical delivery mechanismNephrosisNephropathy
Medical systems and methods for treating kidney disease alone, heart failure alone, kidney disease with concomitant heart failure, or cardiorenal syndrome are described. The systems and methods are based on delivery of a chimeric natriuretic peptide to a patient. Methods for increasing peptide levels include direct peptide delivery via either an external or implantable programmable pump.
Owner:CAPRICOR THERAPEUTICS

Amyloid beta-protein 3(pE)-42 antibodies and uses thereof

AβN3pE-42 is a β amyloid protein that accumulates specifically as a major constituent of senile plaque in the brains of both sporadic and familial Alzheimer's disease patients. The invention provides antibodies that specifically recognize AβN3pE-42 and can be expected to have a strong β amyloid-removing action. Particularly, humanized antibodies against AβN3pE-42 are useful to treat human neurodegenerative diseases. Further, since AβN3pE-42 is localized in the brain, the antibodies of the invention can avoid side effects such as kidney disorders caused by the formation of antigen-antibody complex in the blood. An agent for gene therapy using a vector in which a cDNA encoding a protein comprises the antigen-binding region of the antibody can be an efficient therapeutic drug for removing β amyloid from the brain.
Owner:SAIDO TAKAOMI +1

Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA

InactiveUS20090105173A1Increased riskPrevent ototoxicitySugar derivativesGenetic material ingredientsDiseaseEprotirome
The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from acute renal failure or other kidney diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.
Owner:QUARK FARMACUITIKALS INC

Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof

This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder. This invention provides compounds of oleanene triterpenoidal saponin in nature with the characteristics that at least one angeloyl group attache to Carbon 21 or / and 22, or / and linked to the sugar. The compounds of the present invention have various pharmaceutical and therapeutic applications.
Owner:PACIFIC ARROW

Method for the early detection of renal injury

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.
Owner:DEVARAJAN PRASAD +1

Use of vitamin Ds to treat kidney disease

Disclosed are compositions containing a VDRA / Vitamin D analog to treat or prevent kidney disease, including chronic kidney disease. The present invention also relates to methods of treating kidney disease by administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a VDRA / Vitamin D analog. Compositions according to the invention include a VDRA / Vitamin D analog and at least one of the following agents: an ACE inhibitor, an angiotensin (II) receptor blocker (ARB) and aldosterone blocker in therapeutically effective amounts to inhibit renin production or inhibit activation of the renin-angiotensin-aldosterone system. Preferred compositions contain paricalcitol with at least one of these other agents. Such combinations can avoid ACE inhibition escape and aldosterone escape with subsequent increase in angiotensin (II) and aldosterone generation.
Owner:ABBOTT LAB INC

Quinoline derivatives as pi3 kinase inhibitors

Invented is a method of inhibiting the activity / function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.
Owner:GLAXO SMITHKLINE LLC

Systems and methods for characterizing kidney diseases

The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.
Owner:RENOVAR

Devices for Detecting Renal Disorders

Devices for diagnosing, monitoring, or determining a renal disorder in a mammal are described. In particular, devices for diagnosing, monitoring, or determining a renal disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.
Owner:MYRIAD RBM INC

Remedy or preventive for kidney disease and method of diagnosing kidney disease

InactiveUS20060293256A1Efficient and accurate diagnosisEfficient and accurate detectionBiocideOrganic chemistryDiseaseNephrosis
A novel agent for therapy and / or prevention of kidney diseases as well as a diagnostic method (detection method) of kidney diseases is disclosed. The agent for therapy and / or prevention of kidney diseases comprises as an effective ingredient a substance which inhibits casein kinase 2. The diagnostic method of kidney diseases according to the present invention comprises measuring activity or content of casein kinase 2, or measuring expression amount of casein kinase 2 gene in a sample separated from body.
Owner:TORAY IND INC

Compounds and methods of treating hypertension

InactiveUS20140303144A1Speed up the flowDecreasing sodium reabsorptionBiocideOrganic chemistryDiseaseBlood flow
Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α2B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.
Owner:MEDIVATION TECH INC

Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof

InactiveUS20050220910A1Preventing cerebral agingEnhance memoryBiocideSugar derivativesRheumatismHeadaches
This invention provides compositions, methods and process of producing extracts from Xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for treating cancer, arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder, impotence and premature ejaculation; for preventing cerebral aging; for improving memory, cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's disease or other diseases caused by cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder. This invention provides compounds comprising at least one sugar, a triterpene, such as Sapogenin, and at least one side chains at Carbon 21 and 22, such as Angeloyl groups. The compounds of the present have various pharmaceutical and therapeutic applications.
Owner:PACIFIC ARROW

Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof

InactiveUS7727561B2Preventing cerebral agingEnhance memoryBiocideSugar derivativesRheumatismArthritis
This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder. This invention provides compounds of oleanene triterpenoidal saponin in nature with the characteristics that at least one angeloyl group attached to Carbon 21 or / and 22, or / and linked to the sugar. The compounds of the present invention have various pharmaceutical and therapeutic applications.
Owner:PACIFIC ARROW

Apparatus and methods for diagnosing renal disorders

The present invention provides a system comprising an array of chemically sensitive sensors based on coated single walled carbon nanotubes, for measuring volatile organic compounds indicative of renal failure. Methods of breath analysis for diagnosing chronic, acute and end-stage renal failure are disclosed.
Owner:TECHNION RES & DEV FOUND LTD

Naphthyl sulfamide amino acid derivative, preparation method and medical application thereof

The invention discloses a naphthyl sulfamide amino acid derivative, a preparation method and medical application thereof. A naphthyl sulfamide amino acid derivative R3 substituent group represents a substituent group with an amino acid structure; the amino acid structure refers that the substituent group at least contains one carboxyl and one secondary amine or tertiary amine, and the substituentgroup is connected onto a mother nucleus through the secondary amine or the tertiary amine. The naphthyl sulfamide amino acid derivative provided by the invention can interfere with Keap1-Nrf2 combination and activate Nrf2, so that inflammatory injury is reduced, an inflammation microenvironment is improved, and the naphthyl sulfamide amino acid derivative has potential anti-inflammatory activity.The technician in the field knows that an Nrf2 activating agent can be used for inhibiting inflammatory reaction of diseases, so that the compound provided by the invention can be used for preparingan anti-inflammatory drug for treating diseases associated with inflammation, including chronic obstructive pulmonary diseases, Alzheimer diseases, Parkinson, atherosclerosis, chronic renal diseases,diabetes, intestinal inflammation, rheumatoid arthritis and the like.
Owner:CHINA PHARM UNIV

New biomarkers for assessing kidney diseases

The present invention relates to a metabolic biomarker set for assessing kidney disease comprising at least two amino acids, at least two acylcarnitines and at least two biogenic amines. Moreover, the present invention relates to a method for assessing kidney disease in a mammalian subject which comprises obtaining a biological sample, preferably blood and / or urine, from the subject and measuring in the biological sample the amount of at least two amino acids, of at least two acylcarnitines and of at least two biogenic amines, as well as to a kit adapted to carry out the method. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess kidney disease.
Owner:BIOCRATES LIFE SCIENCES AG

Method of forming vascularized kidney tissue

A method for constructing a stable bioactive mammalian embryonic kidney is described herein. A kidney so constructed requires no artificial support, nor porous man made membranes or tubing to effectuate its biological function of filtering body fluids. A single donor embryonic kidney, or fragment thereof, can produce a great number of functional kidneys suitable for treating subjects with various kidney disorders. It is anticipated that said in vitro produced kidney would be less, or not at all, antigenic when transplanted into a subject, because of its embryonic character and artificial propagation in culture. This method of producing a functional organ can be useful in cloning other organ structures containing inducible epithelial tissues.
Owner:RGT UNIV OF CALIFORNIA

Compositions and methods for prostate and kidney health and disorders, an herbal preparation

A composition including an aliquot of the herb Herba Epimedii; and an aliquot of at least three supplemental herbs selected from the group consisting of Fructus Rosae Laevigatae; Fructus Rubi; Fructus Psoralea; Radix Morindae Officinalis; Fructus Schisandrac Chinensis; Fructus Ligustri Lucidi; Semen Cuscutae; and Radix Astragali. A composition including icariin; ursolic acid; ellagic acid; psoralen; deoxyschizandrin; oleanolic acid; quercetin; aslvagaloside; and an extract of the herb Radix Morindae Officinalis. Methods including administering a composition directed at treatment of various kidney disorders or the promotion of kidney health and to the overall health of the kidney, including the use of a composition in the treatment of prostate cancer, prophylatic prostate health, reduction of polyuria, incontinence, proteinuria, as well as for sexual satisfaction.
Owner:SIBONI GRP

Compositions and methods for prostate and kidney health and disorders, an herbal preparation

A composition including an aliquot of the herb Herba Epimedii; and an aliquot of at least three supplemental herbs selected from the group consisting of Fructus Rosae Laevigatae; Fructus Rubi; Fructus Psoralea; Radix Morindae Officinalis; Fructus Schisandrac Chinensis; Fructus Ligustri Lucidi; Semen Cuscutae; and Radix Astragali. A composition including icariin; ursolic acid; ellagic acid; psoralen; deoxyschizandrin; oleanolic acid; quercetin; aslvagaloside; and an extract of the herb Radix Morindae Officinalis. Methods including administering a composition directed at treatment of various kidney disorders or the promotion of kidney health and to the overall health of the kidney, including the use of a composition in the treatment of prostate cancer, prophylatic prostate health, reduction of polyuria, incontinence, proteinuria, as well as for sexual satisfaction.
Owner:SIBONI GRP

Inhibitors of protein kinase c isoforms and uses thereof

Inhibitors of mammalian protein kinase C isoforms that comprise an inhibitor moiety, which is capable of inhibiting protein kinase activity, operatively associated with a peptide recognition element (PRE), which has an affinity for one or more PKC isoforms are provided. The targeted inhibitory molecules (TIMs) of the present invention are capable of inhibiting one or more PKC isoforms. The TIMs can be designed to target a specific PKC isoform by selection of a PRE component that is shown to preferentially target that PKC isoform. The TIMs are useful as therapeutic agents in the treatment of PKC-related diseases and disorders, such as cancer, psoriasis, angiogenesis, restenosis, atherosclerosis, cardiovascular disease, hypertension, diabetes, neurological disorders, rheumatoid arthritis, kidney disorders, inflammatory disorders and autoimmune disorders.
Owner:PHARMAGAP

Probiotic composition at least comprising bifidobacterium bifidum w23 and capable of controlling intestinal barrier function

The disclosure relates to the field of medicine and nutrition, more specifically, to the field of treatment and prevention of human disorders such as depression, rumination, aggression, migraine, autistic spectrum disorders (including autism and ADHD), schizophrenia, chronic fatigue, kidney disorders, metabolic syndrome or diabetes type II. The disclosure provides a pharmaceutical or food composition or a supplement comprising a multispecies probiotic composition at least comprising Bifidobacterium bifidum W23 for use in the treatment or prevention of disorders in humans and methods to use such a pharmaceutical or food composition or a supplement.
Owner:WINCLOVE HLDG BV

Method for detecting renal disease comprising measuring human megalin in urine

This invention provides a diagnostic kit and a diagnostic marker used for diagnosing a renal disease. This invention also provides a method for detecting a renal disease comprising measuring at least one type of human megalin existing in urine selected from among full-length human megalin and human megalin fragments of (i) to (iii): (i) full-length human megalin; (ii) a human megalin endodomain fragment lacking a human megalin ectodomain; and (iii) a human megalin ectodomain fragment lacking a human megalin endodomain.
Owner:NIIGATA UNIVERSITY +2

Naphthalene sulfonamide compound and preparation methods and applications thereof

The invention discloses a naphthalene sulfonamide compound and preparation methods and applications thereof. The naphthalene sulfonamide compound provided by the invention can interfere with Keap1-Nrf2 binding and activate Nrf2 so as to alleviate inflammatory damage and improve inflammatory microenvironment, has potential anti-inflammatory activity, and can be used for preparing anti-inflammatory medicine for the inflammatory damage of many inflammation-related diseases. The diseases include chronic obstructive pulmonary disease (COPD), Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic kidney disease (CKD), diabetes, intestinal inflammation, rheumatoid arthritis and the like.
Owner:CHINA PHARM UNIV

Cell death inhibitor

InactiveUS20060034832A1Prevent serum depletion-induced cell deathIncrease gene expressionCompound screeningNervous disorderAutoimmune conditionAutoimmune disease
The cell death inhibitor comprising a substance capable of binding to macrophage migration inhibitory factor is useful as a preventive / therapeutic agent for, e.g., heart diseases, neurodegenerative diseases, cerebrovascular diseases, central nervous infections, traumatic diseases, demyelinating diseases, bone / joint diseases, kidney diseases, liver diseases, myelodysplastic diseases, arteriosclerosis, diabetes, pulmonary hypertension, sepsis, inflammatory bowel diseases, autoimmune diseases, failure accompanying rejection in organ transplantation, AIDS, cancer, etc.
Owner:TAKEDA PHARMA CO LTD

Agentfor reducing side effects of diclofenac

The present invention relates to reduction of side effects of diclofenac or a salt thereof An agent for reducing side effects of diclofenac or a salt thereof which comprises ornoprostil. It is expected that a combination agent of diclofenac or a non-toxic salt thereof and ornoprostil is comparable to even superior to marketed diclofenac tablets or Arthrotec tables in effects and fast-acting property while showing little side effects (particularly digestive disorders, gastric ulcer, diarrhea / vomiting and renal disorder) and exerting excellent antipyretic, analgesic and antiinlfammatory effects. Also, by formulating the combination agent into a preparation of separation type pharmaceutical preparation, the stability of ornoprostil can be improved.
Owner:ONO PHARMA CO LTD

Adsorbents for oral administration, remedies or preventives for kidney diseases and remedies or preventives for liver diseases

An adsorbent for oral administration, characterized by comprising a spherical activated carbon prepared from a thermosetting resin as a carbon source, wherein a diameter is 0.01 to 1 mm, and a specific surface area determined by Langmuir's adsorption equation is 1000 m<2> / g or more; and an adsorbent for oral administration, characterized by comprising a surface-modified spherical activated carbon prepared from a thermosetting resin as a carbon source, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m<2> / g or more, a total amount of acidic groups is 0.40 to 1.00 meq / g, and a total amount of basic groups is 0.40 to 1.10 meq / g. The adsorbents for oral administration exhibit a useful selective adsorbability, that is, a less adsorbability of useful substances in a body, and a greater adsorbability of toxic substances.
Owner:KUREHA KAGAKU KOGYO KK
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products